Claritas iPET™ has been approved by the Australian Therapeutic Goods Administration, enabling hospitals to produce sharper and clearer PET scans. This regulatory green light may allow for shorter scan times or reductions in radiation dosage, improving patient care and comfort.
Subscribe
Biotechnology
Claritas iPETTM Approved by Australia TGA to Supply the Medical Software Device for Image Processing Enabling Diagnostic Quality Images from Short Scan Time and/or Low Dose PET, PET-CT/MRI Scans
Key Takeaways:
- Claritas iPET™ now approved by Australia’s TGA
- Enhanced images possible from short-scan or low-dose PET scans
- Software integrates seamlessly with existing hospital systems
- Technology is equipment-agnostic, supporting multiple manufacturers
- Claritas specializes in AI-based image enhancement, noise reduction, and segmentation
Background and Significance
Claritas NucMed Technologies Ltd has received approval from the Australian Therapeutic Goods Administration (TGA) to supply its Claritas iPET™ software. Already cleared and used in multiple jurisdictions, Claritas iPET™ is designed to enhance noisy or unclear Positron Emission Tomography (PET) scans for improved visibility and sharpness. This milestone underscores Claritas’s commitment to leveraging advanced technologies for the benefit of clinicians and patients alike.
The Technology Behind Claritas iPET™
Claritas iPET™ focuses on several key image-processing capabilities, including noise reduction, segmentation, and advanced image enhancement. According to the company, these features help generate diagnostic-quality images from shorter scan times or lower radiation doses. Being agnostic to equipment type and manufacturer, the software can be integrated into existing hospital workflows without requiring a complete overhaul of equipment.
Impact on Australian Healthcare
With TGA approval, Australian healthcare providers may see improved accuracy in diagnosing conditions that rely on PET imaging. Shorter scan times can boost patient throughput and comfort, while lower doses of radiation can bolster safety. By supplying clearer images, clinicians can potentially identify fine lesions more effectively, offering a new layer of confidence in diagnostic outcomes.
Looking Ahead
Claritas’s advancements in AI-driven image processing opened the door for a more efficient approach to medical imaging. As the company’s technology continues to roll out to new regions, its wide compatibility and user-friendly design could make Claritas iPET™ a valuable tool for hospitals around the globe. The TGA approval reinforces the wider potential of such software innovations—even beyond PET imaging—for the future of healthcare.
